Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.
Regional Deposition in Generic Dry Powder Inhalers
Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.
Faster, Cost-Effective Alternative to Generic Bioequivalence
Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.
Elucidating Molecular- and Particle-Level Changes during the Annealing of a Micronized Crystalline Drug
Nanopharm explores annealing in micronized DPIs for drug development. Focus on molecular changes and SFE in Dry Powder Inhaler formulations.
Mixed Kinetic Model of Inhaled Corticosteroid Dissolution
Explore the dissolution kinetics of inhaled pharmaceuticals in dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI).
Automated Classification of DPI Agglomerate Particles
Explore automated classification of dry powder inhaler particles using Cluster Analysis and Morphologically Directed Raman Spectroscopy.
Alternative regulatory path for generic Respiratory Products
Explore Nanopharm’s SmartTrack, an alternative solution for FDA approval of generic inhalation drug delivery products.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
Characterizing Nasal Suspensions for Regulatory and Scientific Purposes
Explore Nanopharm’s in-depth research on particle size and its role in in vitro bioequivalence for nasal drug delivery. Discover how particle sizing impacts regulatory compliance and drug efficacy.
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers
Explore Nanopharm’s in-depth in vitro study on dry powder inhalers (DPIs). Learn how Computational Fluid Dynamics and Particle Size Distribution contribute to device performance and comparability.
